Related Experiment Video
Updated: Aug 1, 2026

07:16
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
34.3K
Global Research Progress on Radiofrequency Ablation in Cardiology
Chukwuka Elendu1, Nkechi P Ogwu2, Alexander U Okatta3
1Federal University Teaching Hospital, Owerri, Nigeria.
Annals of Medicine and Surgery (2012)
|March 20, 2025
Summary
Radiofrequency ablation (RFA) is a key treatment for cardiac arrhythmias like atrial fibrillation. Advances are improving its safety and effectiveness, with ongoing research into new technologies and long-term outcomes.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Technology
Background:
- Radiofrequency ablation (RFA) is a minimally invasive treatment for cardiac arrhythmias.
- It is widely used for conditions including atrial fibrillation and ventricular tachycardia.
- Technological progress has significantly improved RFA's efficacy and safety.
Purpose of the Study:
- To review the evolution, global trends, and comparative outcomes of RFA.
- To identify challenges and emerging technologies in RFA for cardiac arrhythmias.
- To highlight research gaps and the future potential of RFA in cardiology.
Main Methods:
- Systematic review and synthesis of current evidence on RFA.
- Analysis of historical data, global adoption trends, and comparative studies.
- Identification of challenges, emerging technologies, and research gaps.
Main Results:
- RFA adoption is increasing globally, with significant contributions from North America, Europe, and Asia.
- Outcome variability exists due to patient populations, techniques, and healthcare systems.
- Challenges include complications, patient selection, and long-term efficacy, with AI and advanced imaging offering solutions.
Conclusions:
- RFA is a critical tool in managing cardiac arrhythmias, with continuous innovation enhancing its utility.
- Further research is needed on long-term outcomes and complex arrhythmia applications.
- Emerging technologies promise to refine RFA procedures and expand therapeutic applications.
Related Concept Videos
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

